Welcome to our dedicated page for Cencora news (Ticker: COR), a resource for investors and traders seeking the latest updates and insights on Cencora stock.
Cencora, Inc. reports news around its role as a global pharmaceutical solutions organization that distributes branded, generic and specialty pharmaceuticals to pharmacies, hospital networks and healthcare providers. Company updates also cover commercialization services for pharmaceutical and medical-device manufacturers, specialty drug logistics through World Courier, animal health distribution through MWI Animal Health and international wholesale activity following the Alliance Healthcare acquisition.
Recurring developments include fiscal operating results, gross profit drivers, LIFO effects, GLP-1 product mix and performance in U.S. Healthcare Solutions. News also covers completed acquisitions such as OneOncology and Retina Consultants of America, senior note financing, shareholder and governance matters, and executive leadership transitions.
Cencora (NYSE:COR) updated its fiscal year 2026 outlook and expanded its share repurchase capacity. The company now expects adjusted diluted EPS of $17.70–$17.90, raising the low end from $17.65. Recent opportunistic buybacks support its plan to repurchase $1.0 billion of stock by end-2026. On May 20, 2026, the board authorized a new $2.0 billion share repurchase program, in addition to $382 million remaining under the May 2024 authorization. Guidance is provided on a non-GAAP adjusted EPS basis, excluding various litigation, tax, restructuring, and other specified items.
Cencora (NYSE: COR) reported fiscal 2026 second quarter revenue of $78.4 billion, up 3.8% year-over-year, GAAP diluted EPS of $8.40 and adjusted diluted EPS of $4.75. The company raised full-year adjusted EPS guidance to $17.65–$17.90, expects to repurchase $1.0 billion of shares by end of calendar 2026, and declared a quarterly dividend of $0.60 per share payable June 1, 2026.
Quarter results reflected the February 2026 OneOncology acquisition, higher operating expenses, a $1.1 billion remeasurement gain, and guidance for ~4–6% revenue growth for fiscal 2026.
Cencora (NYSE: COR) will release Second Quarter Fiscal 2026 results on Wednesday, May 6, 2026, prior to the opening of trading on the New York Stock Exchange, and will host a conference call at 8:30 a.m. ET the same day.
The live webcast will be available at investor.cencora.com, with teleconference dial‑in details, meeting ID and access code provided; a replay will be posted about one hour after the call and remain available for one year. Cencora is ranked #10 on the Fortune 500 and reports >$300 billion in annual revenue.
Cencora (NYSE: COR) signed a definitive agreement to acquire EyeSouth Partners’ retina business for $1.1 billion, adding the affiliated retina physicians to Retina Consultants of America (RCA).
Cencora expects the deal to be slightly accretive to adjusted diluted EPS in the first 12 months, is subject to regulatory approvals, and reaffirmed fiscal 2026 guidance that does not assume closing.
Cencora (NYSE: COR) announced that James F. Cleary will retire as Executive Vice President and Chief Financial Officer effective June 30, 2026, and that the company has engaged an executive search firm to find his successor. Cleary will advise through the end of 2026.
Cencora reaffirmed its adjusted diluted EPS guidance range of $17.45 to $17.75 for fiscal 2026.
Cencora (NYSE: COR), Covetrus and MWI Animal Health announced a definitive merger to create an integrated animal health platform. The transaction values MWI at an enterprise value of $3.5 billion.
Cencora will receive $1.25 billion cash, $800 million preferred equity/b and
Cencora (NYSE: COR) closed a $3.0 billion underwritten offering of senior notes across five tranches: $500M 3.950% due 2029, $500M 4.250% due 2030, $500M 4.600% due 2033, $1.0B 4.900% due 2036 and $500M 5.650% due 2056.
According to the company, net proceeds will repay amounts outstanding under its 364-Day Term Credit Agreement used to fund the OneOncology acquisition, with any remaining proceeds for general corporate purposes. Joint book‑running managers were Citigroup, J.P. Morgan, BofA and Wells Fargo.
Cencora (NYSE: COR) priced a $3.0 billion underwritten senior note offering across five tranches due 2029, 2030, 2033, 2036 and 2056 with coupon rates from 3.950% to 5.650%.
Proceeds are intended to repay amounts under Cencora’s 364-Day Term Credit Agreement used to fund the OneOncology acquisition, with closing expected February 13, 2026. The offering is made from an effective shelf registration filed November 26, 2024.
Cencora (NYSE: COR) reported fiscal 2026 first quarter results for the period ended December 31, 2025: revenue $85.9B (+5.5% YoY), GAAP diluted EPS $2.87, and adjusted diluted EPS $4.08 (+9.4% YoY). The company completed the acquisition of OneOncology and raised adjusted operating income guidance to +11.5% to +13.5% while reaffirming adjusted diluted EPS guidance of $17.45–$17.75 for fiscal 2026. A quarterly dividend of $0.60 per share was declared, payable March 2, 2026.
Cencora (NYSE: COR) elected Ellen Cooper to its Board of Directors, effective January 20, 2026. Ms. Cooper is chairman, president and CEO of Lincoln Financial and became CEO in May 2022. Her background includes roles as Executive VP and Chief Investment Officer at Lincoln, Managing Director and Global Head of Insurance Strategy at Goldman Sachs Asset Management, Chief Risk Officer for AEGON Americas, and Principal at Ernst & Young.
She holds a BBA from Temple University and professional credentials including Fellow of the Society of Actuaries, Chartered Enterprise Risk Analyst, and Chartered Financial Analyst.